Rapid Micro Biosystems (NASDAQ:RPID) COO John Addington Wilson Sells 4,610 Shares

Rapid Micro Biosystems, Inc. (NASDAQ:RPID) COO John Addington Wilson sold 4,610 shares of the stock in a transaction on Monday, February 9th. The stock was sold at an average price of $3.78, for a total transaction of $17,425.80. Following the sale, the chief operating officer owned 257,768 shares of the company’s stock, valued at approximately $974,363.04. This represents a 1.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Rapid Micro Biosystems Price Performance

Shares of Rapid Micro Biosystems stock traded up $0.33 on Tuesday, hitting $4.08. The company’s stock had a trading volume of 306,371 shares, compared to its average volume of 371,737. The company has a market capitalization of $180.83 million, a P/E ratio of -4.04 and a beta of 1.38. Rapid Micro Biosystems, Inc. has a 52-week low of $1.86 and a 52-week high of $4.94. The company has a quick ratio of 2.95, a current ratio of 4.23 and a debt-to-equity ratio of 0.42. The firm has a fifty day moving average price of $3.66 and a 200-day moving average price of $3.39.

Rapid Micro Biosystems (NASDAQ:RPID) last released its earnings results on Friday, November 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.26). The firm had revenue of $7.84 million during the quarter, compared to the consensus estimate of $7.60 million. Rapid Micro Biosystems had a negative net margin of 145.11% and a negative return on equity of 73.90%. On average, equities research analysts expect that Rapid Micro Biosystems, Inc. will post -1.1 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

RPID has been the subject of a number of recent research reports. Wall Street Zen lowered Rapid Micro Biosystems from a “hold” rating to a “sell” rating in a research note on Saturday, January 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Rapid Micro Biosystems in a research report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $8.00.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in Rapid Micro Biosystems by 6.7% in the 3rd quarter. Vanguard Group Inc. now owns 965,018 shares of the company’s stock worth $3,223,000 after buying an additional 60,655 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Rapid Micro Biosystems by 6.3% during the 4th quarter. Geode Capital Management LLC now owns 217,568 shares of the company’s stock worth $631,000 after purchasing an additional 12,881 shares in the last quarter. Evernest Financial Advisors LLC boosted its holdings in shares of Rapid Micro Biosystems by 355.1% in the 3rd quarter. Evernest Financial Advisors LLC now owns 200,234 shares of the company’s stock worth $669,000 after acquiring an additional 156,234 shares in the last quarter. Susquehanna International Group LLP raised its position in Rapid Micro Biosystems by 12.6% in the 3rd quarter. Susquehanna International Group LLP now owns 58,387 shares of the company’s stock worth $195,000 after purchasing an additional 6,528 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of Rapid Micro Biosystems by 37.8% during the third quarter. Dimensional Fund Advisors LP now owns 55,642 shares of the company’s stock worth $186,000 after purchasing an additional 15,255 shares during the period. Institutional investors own 52.60% of the company’s stock.

About Rapid Micro Biosystems

Rapid Micro Biosystems (NASDAQ: RPID) develops and commercializes automated microbial detection and contamination control solutions for the life sciences industry. Its flagship offering, the Growth Direct® System, leverages digital imaging and proprietary growth indicator plates to identify and count microorganisms more rapidly than traditional culture-based methods. The company’s technology platform is designed to streamline quality control workflows in pharmaceutical, biotechnology and vaccine manufacturing settings, helping clients reduce release times and improve operational efficiency.

In addition to the Growth Direct® System, Rapid Micro Biosystems offers an integrated suite of software and consumables that support automated data capture, analysis and reporting.